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PROGRAMME 
Wednesday 17th May – Day One 
8:00 am – 9:00 am Registration 
9:00 am – 9:30 am Opening and Welcome  Conference Room II 
9:30 am – 10:15 am  Keynote Presentation: 
Kerstin Stenius: Towards control by management? On alcohol and drug problems in the history of Nordic welfare  Conference Room II 
Chair: Vibeke A. Frank 
10:15 am – 10:45 am  MORNING TEA 
Session Theme Drug policy differentiation 
 
Conference Room II 
Policy responses to drug problems 
 
Room A 
Debating drugs in media 
 
Room C 
New psychoactive substances 
 
Room D 
Discussant chair Vibeke A. Frank Nicola Singleton Steven Jonas Peter Reuter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
10:45 am – 12:15 pm  
Panel 1: Drug policy differentiation: accom-
modating diversity and marginality  
 
Panelists:  
Elizabeth Ettorre 
Emma Wincup 
Daniel Bear 
Aileen O’Gorman 
 
Aims: Drug use by women, minority ethnic 
and marginalised groups is differentially stig-
matised and problematised. These same so-
cial groups experience disproportionate lev-
els of drug-related harms. Despite this, drug 
policies focus on addressing individual drug-
using behaviours, through law enforcement, 
treatment, and outreach, as if these behav-
iours were context free and unaffected by 
structured inequalities. Rarely, in the devel-
opment of drug policy, is the unequal expe-
rience of harms predicated by gender, race 
and class acknowledged or addressed. 
Moreover, the implementation of these poli-
cies can lead to harms which are dispropor-
tionately felt by these social groups. The 
presentations in this panel will explore the 
differentiated impact of drug policies and 
drug-related harms on women, trans men 
and women, black and minority ethnic 
groups, and marginalised socio-economic 
groups and communities. Drawing on case 
studies from their research, panellists will 
frame their presentations around the follow-
ing questions: what is the impact of criminal 
justice; public health; and recovery ap-
proaches to drug policy on these social 
groups? How can drug policies best address 
difference, marginality and intersectionality 
Alison Ritter, Caitlin Hughes, Kari Lancas-
ter, Rob Hope  
 
Drug detection dogs seen through the 
eyes of the Advocacy Coalition Frame-
work compared to Multiple Streams: the 
science-policy  interface   
 
Lena Eriksson 
 
The needle exchange debate in Stock-
holm City Council and Swedish Parlia-
ment during the 21st century 
 
 
Robert Csák, József Rácz 
 
How environmental factors can increase 
the risks of PWIDs - a case study of Buda-
pest, Hungary  
 
 
Claudia Rafful, Orozco R, Rangel G, Da-
vidson P, Gonzalez-Zúñiga P, Werb D, 
Beletsky L, Strathdee SA. 
 
Increased non-fatal overdose risk associ-
ated with involuntary drug treatment in a 
longitudinal study with people who inject 
drugs in Tijuana, Mexico  
 
 
Mauricio Coitiño, Rosario Queirolo, 
Alejandra Triñanes 
 
Same laws, different messages: the fram-
ing effect on the press coverage of the 
regulation of cannabis and alcohol in Uru-
guay  
 
 
Rob Ralphs and Paul Gray 
 
Caught in the act: The impact of the Psy-
choactive Substances Act on vulnerable 
users 
 
 
Alisa Pedrana, Joseph Doyle, Alex 
Thompson, Paul Dietze, Mark Stoove, 
Jacqui Richmond, Judy Gold, Peter Higgs, 
Margaret Hellard 
 
EC!: A partnership to eliminate hepatitis C 
in Australia 
 
 
Marie Jauffret-Roustide 
 
Drug consumption rooms: issues of social 
acceptability in French public debate 
 
Maurits Beltgens 
 
Examining the impact of the UK blanket 
ban on psychoactive substances on the 
UK’s legal high market 
 
 
My Lilja 
 
Drug discourses in Russian parliamentary 
debate 
 
 
12:15 pm – 1:15 pm LUNCH 
 
 
 
 
 
 
 
 
 
 
Wednesday 17th May – Day One 
Session Theme Harms, trends & pleasures 
 
Conference Room II 
Comparative analyses of drug policy and 
drug use 
Room A 
Drug policies and history 
 
Room C 
Different drugs, different policies? 
 
Room D 
Discussant chair Esben Houborg Axel Klein Geoffrey Hunt Aileen O´Gorman 
  
 
 
 
 
 
 
 
 
 
 
 
 
B 
1:15 pm – 2:45 pm  
Mark Monaghan, Ian Hamilton 
 
Risk, benefits and realism: The implica-
tions of the absence of pleasure in public 
health campaigns and interventions 
around cannabis 
 
 
 
Aysel Sultan 
 
Drug policies of Azerbaijan and Germany 
reflected in narratives of high-risk drug 
user adolescents  
Robin Room 
 
Legalising after prohibition: alcohol's les-
sons for other drugs 
 
 
Santiago Cunial 
 
Conflicts around Issues with low political 
salience: explaining the role of the Catho-
lic Church in the debate on drug de-
penalization in Argentina (2009-2014) 
 
 
Peter Reuter; Bryce Pardo; Jonathan 
Caulkins 
 
Can sentences for drug offenses credibly 
reflect differences in the harms of drugs? 
 
 
Anke Stallwitz 
 
Community policy at the micro-social 
level: Utilizing community-mindedness to 
reduce violence in the Vancouver and the 
Stockholm drug scene 
 
David McDonald, Alison Ritter 
 
Innovations in drug policy interventions 
over the past decade: an overview and 
assessment  
 
 
Akash Sood, Atul Ambekar, Ashwani 
Mishra 
 
Can economic analysis of household in-
come and expenditure inform alcohol 
policies? Analysis of household data from 
nationally representative sample from In-
dia 
 
Bryce Pardo 
 
What relationship does access to canna-
bis have on the consumption of synthetic 
cannabinoids?  
 
 
Luca Giommoni, Peter Reuter, Beau 
Kilmer 
 
The perils of cross national comparisons of 
drug prevalence: the effect of survey mo-
dality  
Mitch Librett  
 
Every doctor a cop; every cop a doctor 
 
 
April Henning 
 
The escalating of the war on doping in 
2016 
 
Jasmina Burdzovic Andreas; Anne Line 
Bretteville-Jensen 
 
Ready, willing, and able: The role of can-
nabis use opportunities in understanding 
adolescent cannabis use  
 
 
Majid Alaee, Mahmoud Jahan Tigh 
 
A study on the prevalence of medica-
tion/polymedication abuse in Iran  
Yun Huang 
 
“With a mill-stone about her neck”: 
China’s participation of the 1924-1925 
Geneva Opium Conferences and its im-
pacts 
 
 
2:45 pm – 3:15 pm AFTERNOON TEA 
  
Wednesday 17th May – Day One 
Session Theme Production and distribution of cannabis 
and methamphetamine 
Conference Room II 
Harm reduction 
 
Room A 
Methadone treatment 
 
Room C 
Prison, treatment & drug use 
 
Room D 
Discussant chair Jonathan Caulkins Susanne MacGregor Bagga Bjerge Emma Wincup 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C 
3:15 pm – 5:00 pm  
Steven Davenport 
 
Do marijuana stores increase local traffic 
accidents? Evidence from Oregon 
 
 
 
 
Andy Guise, Amen Hamida, Maria Luisa 
Mittal, Claudia Rafful, Peter Davidson, 
Daniel Werb 
 
Harm reduction, choice and pleasure in 
structural responses to injecting initiation; 
insights from qualitative research in the 
Mexico-U.S. border region 
Tim Rhodes, James Ndimbii, Emmy 
Kageha, Frederick Owiti, Steffanie 
Strathdee, Andy Guise  
 
The becoming of methadone treatment 
in Kenya: A qualitative study of imple-
mentation 
 
 
Petr Zeman, Michaela Štefunková, Šárka 
Blatníková, Kateřina Grohmannová, 
Tomáš Koňák, Ivana Trávníčková 
 
Treatment in an unfavourable setting: 
Specialized departments for drug users in 
Czech prisons  
 
Simon Lenton, Vibeke Frank, Monica Bar-
ratt, Gary Potter 
 
Growing practices and the use of chemi-
cal additives among a sample of small 
scale cannabis growers in three countries 
 
 
Kati Kataja 
 
New practices of harm reduction? Sharing 
risk experiences of polydrug use on 
YouTube 
 
 
Roya Noori. Masoud Lotfizadeh, Babak 
Moazen, Nazgol Mostafavinasab, Hoo-
man Narenjiha 
 
Methadone maintenance treatment entry 
and retention among Iranian drug user 
women: A qualitative study in Iran  
Karen Duke 
 
Producing the ‘problem’ of New Psycho-
active Substances (NPS) in  English prisons 
 
 
Mafalda Pardal 
 
“The difference is in the tomato at the 
end”: understanding the role and prac-
tices of cannabis growers operating 
within Belgian cannabis social clubs 
 
Truong Tuan Dung 
 
A qualitative and quantitative study to 
critically explore perceptions of harm re-
duction policy and practice in Vietnam  
Thu T.A. Vuong, Nhu T. Nguyen, Nguyen B. 
Nguyen, Huy L. Pham, Huong Q. Nguyen 
 
From free service to co-payment model: 
Effects of the transition on patient adher-
ence and service quality of the Metha-
done Maintenance Treatment program in 
Vietnam  
 
Yifen Lu, Yichun Yu, and Chuen-Jim Sheu 
 
Evaluation of the deferred prosecution 
practice for drug abusers: An analysis with 
big data in Taiwan 
Jason Ferris 
 
The disruption of Australian domestic 
methamphetamine production: Analysis 
of pseudoephedrine-based medication 
sales data 
 
Steven Hayle 
 
A social structural analysis of needle ex-
change policy in Canada and the UK 
 
 
Atul Ambekar, Alok Agrawal, Ashwani 
Mishra, Ravindra Rao 
 
Do drug policies impede the availability 
of treatment of opioid dependence in In-
dia (and more so for non-injecting opioid 
users)? Analysis of epidemiological data 
from Punjab, India  
 
Torsten Kolind 
 
Prison drug treatment: Increasing overlaps 
between social service and punishment  
 Modupe Onigbogi, Omobola Ojo 
 
Willingness to join drug free clubs by el-
derly persons in Lagos, Nigeria 
 
 
 
Zahra Alammehrjerdi, Afsaneh Moradi 
 
Drug treatment and harm reduction pro-
grams for women in Iran: the first women-
specific health policy in Western Asia 
 
 
Kristy Kruithof, Matthew Davies, Emma 
Disley, Lucy Strang and Kei Ito 
 
Mapping the use of alternatives to coer-
cive sanctions as a response to drug law 
offences and drug-related crimes across 
the EU  
5:30 pm – 7:30 pm WELCOME RECEPTION  
ARoS Aarhus Art Museum 
 
 
 
 
 
 
 
 
 
 
Thursday 18th May – Day Two 
8:30 am – 9:15 am Registration 
9:15 am – 10:00 am Keynote Presentation:  
Alejandro Madrazo Lajous: The Constitutional Costs of the War on Drugs  Conference Room II 
Chair: Beau Kilmer 
10:00 am – 10:30 am  MORNING TEA 
Session Theme Cryptomarkets 
 
Conference Room II 
Performance and image enhancing 
drugs 
Room A 
Alternative regulatory models for 
cannabis 
 
Room C 
Developing drug supply indicators 
Room D 
Discussant chair Monica Barratt & Peter Reuter Katinka van de Ven Simon Lenton Caitlin Hughes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D 
10:30 am – 12:00 pm  
Panel 7: Cryptomarkets – recent empirical 
developments and theoretical perspec-
tives  
 
Panelists:  
David Décaru-Hétu 
Jakob Demant 
Monica Barratt 
Meropi Tzanetakis 
Judith Aldridge 
Rasmus Munksgaard 
Leigh Coney 
 
Aims: Cryptomarket research has ma-
tured in the last few years. A central group 
of researchers, many of whom comprise 
this panel, have been part of establishing 
methods and consolidating formative re-
search (see special issue of IJDP, Volume 
35, 2016). This panel presents new crypto-
market research considering long-term 
measurements, the meanings and uses of 
cryptocurrencies, the relevance for orga-
nized crime and the long standing rele-
vant question of initiation of drug use. The 
aim is to bring together new research to 
further our understanding of the overall 
impact of cryptomarket emergence upon 
global drug markets and health/social 
outcomes. 
 
Panel 8: HED policy panel I: Performance 
and image enhancing drugs 
 
Panelists:  
Katinka van de Ven 
Ask Vest Christensen 
Bertrand Fincoeur 
Anders Vinther 
 
Aims: To explore public health and law 
enforcement perspectives for regulating 
the illicit human enhancement drug (HED) 
market within the EU. A new kind of drug 
use has emerged with the growing preva-
lence of HEDs that have the potential to 
improve human attributes and abilities. 
People are using enhancement drugs for 
various lifestyle purposes such as to lose 
weight, to increase muscle strength and 
size, to look younger and/or to enhance 
sporting performance. In particular the 
use of performance and image enhanc-
ing drugs (PIEDs), a subset of HEDs, are 
growing in popularity in amateur and fit-
ness sports. There is however little robust 
information on the use and supply of 
PIEDs which undermines the evidence-
base for designing and implementing law 
enforcement measures, prevention, harm 
reduction initiatives and treatment. HED 
Panel I brings together knowledge of PIED 
use, problems and markets with a specific 
focus on the EU, whilst seeking to contrib-
ute to practice and policy. 
Panel 5: Alternative regulatory models for 
cannabis in four countries  
 
Panelists:  
Jonathan Caulkins 
Beau Kilmer 
Tom Decorte 
Chris Wilkins 
John Clare 
 
Aims: There is growing popular support for 
the legalisation of cannabis in a number 
of countries around the world but only 
limited awareness of regulatory options 
other than the familiar and problematic 
commercial markets for alcohol and to-
bacco. There is a pressing need to pro-
vide greater detail and context to alterna-
tive non-commercial regulatory regimes 
for cannabis to inform public debate and 
political advocacy. This panel will present 
different regulatory regimes for cannabis 
from a number of countries. Each regula-
tory model reflects the specific legal, insti-
tutional and social environments of can-
nabis use in a country. 
 
 
Panel 3: Developing drug supply indica-
tors to improve policy monitoring, analysis 
and practice  
 
Panelists:  
Nicola Singleton 
Teodora Groshkova 
Roel de Bont 
 
Aims: The panel aims to highlight the 
challenges associated with using supply-
side indicators for policy monitoring and 
analysis in a range of countries and re-
gions and discuss potential ways of im-
proving existing sources, expanding their 
use and identifying new indicators and 
data to provide a more complete and up-
to-date picture of illicit drug production 
and markets and of their impacts. By de-
scribing some methodological develop-
ment work currently underway it aims to 
stimulate the identification of opportuni-
ties for enhancing data collection and 
policy analysis in this area at both na-
tional and regional levels. 
12:00 pm – 1:00 pm LUNCH 
1:00 pm – 1:30 pm POSTER SESSION (room tba) 
  
 
 
 
 
 
 
 
 
 
 
 
Thursday 18th May – Day Two 
Session Theme Darknet and cryptomarkets 
Conference Room II 
Cognitive enhancement drugs 
Room A 
Selling drugs 
Room C 
Drug monitoring and policy indexes 
Room D 
Discussant chair Peter Reuter & Monica Barratt Jeanett Bjønness Kim Møller Claudia Costa-Storti 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E 
1:30 pm – 3:00 pm  
Kristy Kruithof, Judith Aldridge, David Dé-
cary-Hétu, Megan Sim, Elma Dujso, Stijn 
Hoorens.  
 
Drug trade via cryptomarkets: trends, 
wholesale versus retail and shipping 
routes 
  
 
 
 
Panel 9: HED policy panel II: Cognitive en-
hancement drugs  
 
Panelists:  
Jeanett Bjønness 
Scott Vrecko 
Aleksi Hupli 
Gabija Didziokaité 
Marte Ydema 
 
Aims: To explore public health and law 
enforcement perspectives for regulating 
the illicit human enhancement drug (HED) 
market within the EU. A new kind of drug 
use has emerged with the growing preva-
lence of HEDs that have the potential to 
improve human attributes and abilities. 
One strategy for human enhancement is 
the use of cognitive enhancement drugs 
(CEDs); also often referred to as smart 
drugs, study drugs, nootropic or neuroen-
hancers. These are drugs that are pur-
ported to improve mental functions such 
as memory, intelligence, attention, and 
concentration. The most commonly used 
class of drug is stimulants. HED Panel II will 
bring together knowledge about use of 
and perceptions about CEDs among 
young people and contribute to a re-
search-based future policy in the field. 
 
 
 
Cecep Mustafa 
 
”She/he strives for justice that will be 
benefial to the offender, although it will 
abandon legal certainty somewhat”: the 
perceptions of Indonesian judges in  sen-
tencing minor drug offenders 
 
 
 
Peter Meylakhs, Eric Sevigny 
 
Development of a global policy index 
measuring national commitments to HIV 
prevention and treatment among people 
who inject drugs  
Larissa J. Maier, Monica Barratt, Jason Fer-
ris, Adam Winstock  
 
Do zero tolerance drug policies promote 
NPS and darknet market use? 
 
 
 
 
Bernd Werse, Dirk Egger  
 
“I don’t do this because I want to get rich” 
– a comparative analysis of profit oriented 
drug-dealers in Germany  
Vivienne Moxham-Hall, Caitlin Hughes, 
Alison Ritter  
 
The development and application of an 
Australian cannabis law index 
Angus Bancroft, Kim Masson 
 
‘Nice people doing shady things’: The mo-
rality of exchange in darknet cryptomar-
kets  
 
Judith Aldridge, Lisa Williams, Tom De-
corte  
 
Can profitable drug selling activity be un-
derstood as normalized? Drug cryptomar-
ket sellers as drug reform activists  
 
 
 
 
 
 
 
 
 
 
Angelica Meinhofer 
 
Prescription drug monitoring programs: 
the role of asymmetric information on 
drug availability and abuse  
3:00 pm – 3:30 pm AFTERNOON TEA 
3:30 pm – 4:15 pm Keynote Presentation:  
Rosalie Liccardo Pacula:  Into the weeds:  Why details matter for properly evaluating the effects of changing marijuana policies Conference Room II 
Chair: Alex Stevens 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thursday 18th May – Day Two 
Session Theme Different policy, different consequences 
Conference Room II 
Treatment: complexity and comparison 
Room A 
Mapping drug markets in different ways 
Room C 
Costs of drugs 
Room D 
Discussant chair David McDonald Marie Jauffret-Roustide Alison Ritter Beau Kilmer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F 
4:20 pm – 5:30 pm  
Stephen Rolles, Fiona Measham, Ole 
Rogeberg  
 
Using multi criteria decision analysis 
(MCDA) to assess different policy re-
sponses to non-medical heroin use  
 
Bagga Bjerge, Jeppe Oute, Louise Chris-
tensen  
 
Complex cases – complex policies  
 
Julian Broseus, Natacha Gentile, Simon 
Baechler, Marie Morelato, Pierre Esseiva  
 
Studying illicit drug markets through the 
analysis of its central component: how to 
provide intelligence by profiling law en-
forcement seizures  
 
Laura Atuesta 
 
Towards an evaluable drug policy: Analy-
sis of six focus groups in Mexico 
Daniel Mauricio Rico 
 
Alternative development and drugs sup-
ply reduction: who gets the benefits? 
 
 
 
 
Jessica Storbjörk, Jeanette Mugavin  
 
Events in problematic substance users’ 
lives and paths to treatment: comparing 
the prohibitionist Sweden to the harm-
minimizing Australia  
 
Daan van der Gouwe, Tibor Brunt, Magriet 
can Laar, Peggey van der Pol  
 
Purity, adulteration and price of drugs 
bought online versus offline in the Nether-
lands  
 
Anne Line Bretteville-Jensen, Claudia 
Costa Storti, C. Mikulic,S. Trigueiros, F. Pa-
pamalis, P. Piscociu, Kattau  
 
Public expenditure on supply reduction 
policies  
Maria Luisa Mittal, Claudia Rafful, Devesh 
Vashishtha, Patricia Gonzales-Zuniga, Pe-
ter Davidson, Dan Werb, Andy Guise  
 
Drug policy implications of pathways to 
initiation of injection drug use facilitated 
by people who inject drugs in Tijuana, 
Mexico 
 
 
Lynda Berends 
 
Policy reform regarding the ‘problem’ of 
centralized assessment in Victoria’s drug 
treatment sector   
Jonathan Caulkins, Yilun Bao, Imane 
Fahli, Yutian Guo, Krista Kinnard, Mary 
Najewicz, lauren Renaud.  
 
Big data on a big new market: Insights 
about suppliers and customers in Wash-
ington State’s legal cannabis market  
 
Claudia Costa Storti, Charlotte Davies  
 
Estimating costs of drug treatment: main 
challengand concerns  
Frank Renato Casas Sulca 
 
Scenarios and social actors as key deter-
minants of drug policy in Peru: two com-
parative cases on coca leaf control  
SeyedehNazgol Mostafavinasab, Roya 
Noori, Omid Massah, Babak Moazen, Ali 
Farhoudian, Reza Daneshmand, Sepideh 
Aryanfard  
 
Women-only therapeutic community pro-
gram and treatment needs in Iran: the first 
study from the most populated Persian 
Gulf country 
Kim Moeller, Sveinung Sandberg  
 
Putting a price on trust: a qualitative study 
of mid- and upper-level drug dealers´ 
pricing decision 
5:30 pm – 6:30 pm ISSDP Annual General Meeting  Room A 
7:00 pm – 9:30 pm CONFERENCE DINNER at CANblau 
 
 
 
 
 
 
 
 
 
 
Friday 19th May – Day Three 
8:30 am – 9:00 am Registration 
9:00 am – 9:45 am Keynote Presentation: 
Eugene Raikhel: Pathological desire: debating addiction and evidence in Putin's Russia  Conference Room II 
Chair: Esben Houborg 
Session Theme Development and drug policy 
 
Conference Room II 
Researchers and drug use 
 
Room A 
Methodology and drug policy research 
 
Room C 
Research funding sources and conflicts of 
interest 
Room D 
Discussant chair Alejandro Madrazo Lajous Monica Barratt Tom Decorte Alison Ritter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
G 
9:50 am – 11:00 am 
Panel 10: New Perspectives on the inter-
section between development and drug 
policy  
 
Panelists:  
John Collins 
Aileen O’Gorman 
David Mansfield 
Alexander Soderholm 
 
Aims: This panel aims to present case-
study based and novel analysis on the in-
tersections between development and 
drug policy. It does such to influence the 
way in which issues associated with illicit 
drug markets are understood, and indeed 
their ‘root causes’, and to shape the policy 
interventions to these markets. Thus, the 
panel aims to examine how sustainably 
reduce the harms across the whole supply 
chain of illicit drugs. 
 
Workshop:  
Are we ready to come out? Discretion, 
disclosure, identity and the drug re-
searcher’s drug use.  
 
Monica Barratt with Judith Aldridge, Gary 
Potter and Anna Ross  
 
 
 
 
 
 
 
 
 
Katrine Syppli Kohl 
 
Risk, knowledge and willful ignorance: 
Narratives of being knowledgeable in in-
terviews with high-risk drug users  
 
 
 
Panel 4: Research funding sources and 
conflicts of interest: understanding diverse 
policy positions  
 
Panelists:  
Helen Keane 
Robin Room 
Alex Stevens 
Kerstin Stenius 
 
Aims: With this panel we hope to stimu-
late debate around the appropriate role 
(if any) of industry in funding policy-rele-
vant drug research, with a view to inform-
ing future policy of the ISSDP (and IJDP) 
on accepting research that is industry-
funded (where industry includes alcohol, 
tobacco, vaping, pharmaceutical, medici-
nal cannabis, private treatment and gov-
ernment industries that fund research). 
 
 
Rebecca Askew 
 
From apathy to activism: understanding 
drug takers perspectives on the law and 
policy 
 
 
 
Peter Davidson, Rebecca Fielding-Miller, 
Ricky Bluthenthal.  
 
Ethical collaborations between research-
ers and community organisations serving 
people who use drugs 
11:00 am – 11:20 am MORNING TEA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Friday 19th May – Day Three 
Session Theme The Uruguyan cannabis model 
 
Conference Room II 
Drug trafficking 
 
Room A 
Drug user perspectives 
 
Room C 
Policing drugs in festival, club settings 
and on the streets 
Room D 
Discussant chair Pablo Galain-Palermo Gary Potter Torsten Kolind Daniel Bear 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H 
11:20 am – 12:50 pm  
Panel 2: The Uruguyan cannabis model: 
update and open issues  
 
Panelists:  
Pablo Galain Palermo 
Marcos Baudean 
Rosario Queirolo 
Gustavo Robaina 
 
On 10th of December 2013 the Uru-
guayan parliament passed law 19172 es-
tablishing a normative framework which 
allows control of the cannabis market. 
The law establishes a new approach to 
the distribution, consumption and com-
mercialization of cannabis. On the one 
hand, it intends to contribute to the reduc-
tion of the risks and potential damages in-
curred by those persons who use canna-
bis for medicinal or recreational purposes 
(public health), and on the other hand as 
a measure to improve public safety and 
coexistence. The model proposes to im-
plement a regulated distribution of can-
nabis in which the state will have a mo-
nopoly of the substance’s distribution. 
Many things have changed in the country 
as a result of the new legislation. What 
are the preliminary results and lessons 
that can be learned from this period?  
 
Sheryl McCurdy 
 
Pawns in Makran: Tanzanians, debt bond-
age, and drug trafficking strategies  
Samhita Bhushan, Atul Ambekar, Abhay 
Jain  
 
Attitudes and perceptions of retailers and 
consumers of legal cannabis (bhang) in 
India  
Simon Lenton, Monica Barratt, Jodie Grigg 
 
Deterrent effects of drug detection dogs 
at Australian outdoor music festivals: De-
terrent, detection and iatrogenic effects  
 
Allan Gillies 
 
The Evolution of State-Narco Networks in 
Post-Transition Bolivia (1982-1993): Gov-
ernance, political order and processes of 
transition 
  
Osasuyi Dirisu, Darren Shickle, Helen Elsey.  
 
Perspectives on young cannabis users 
within the Nigerian policy context: The 
paradox of criminalization as a deter-
rence strategy  
 
  
Caitlin Hughes, Vivienne Moxham-Hall, 
Alison Ritter, Rob McCoun, Don Weather-
burn  
 
Going out in Sydney: a three month pro-
spective study of the impacts of street-
level policing on illicit drug use at outdoor 
music festivals and licensed entertain-
ment precincts  
 
Paul Gray, Rob Ralphs, Anna Norton.  
 
‘Green heroin’: Synthetic cannabinoid use 
amongst the homeless in the north of 
England  
Thomas Friis Søgaard, Esben Houborg 
  
Voices of the banished: young people’s 
experiences of and resistance to nightlife 
zonal banning orders  
 
Charlotte de Kock, Bert Hauspie, Ilse Der-
luyn, Tom Decorte, Wouter Vanderplas-
schen, Julie Schamp.  
 
A qualitative exploration of perceived dis-
crimination, ethnic identity and social net-
work and their relation to substance use in 
people with a Turkish and Eastern-Euro-
pean migration background in Ghent, 
Belgium  
 
M. Morales, ML. Mittal, T. Rocha, C. Rafful, 
E. Clairgue, J. Arredondo, J. Cepeda, SA. 
Strathdee, L. Beletsky  
 
Translating drug policy reform: A qualita-
tive study of police officer perspectives in 
implementing the Narcomeudeo law re-
forms in Tijuana, Mexico  
12:50 pm – 1:45 pm LUNCH  
 
 
 
 
 
 
 
 
 
 
 
 
 
Friday 19th May – Day Three 
 
Session Theme Medical cannabis 
Conference Room II 
New developments in harm reduction 
Room A 
New theories in drug policy? 
Room C 
Human rights and UN language 
Room D 
Discussant chair Rosalie Liccardo Pacula Alex Stevens Thomas Friis Søgaard Angela Me 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I 
1:45 pm – 3:15 pm  
Davide Fortin, Marcus Asplund 
 
The effects of full legalization on the med-
ical cannabis market in Colorado: Evi-
dencefor prescription policy  
 
 
 
Panel 6: New developments in harm re-
duction: panel of the ISSDP/ESC joint 
working group on European drug policy 
 
Panelists:  
Camille Stengel 
William Floodgate 
Fiona Measham 
Tristan Duncan 
 
Aims: Harm reduction is an approach that 
was developed in European countries, 
originally to counter the spread of blood 
borne viruses. In recent years, if has faced 
challenges, including new patterns of 
drug use, increases in drug-related deaths 
and competition from the 'recovery 
agenda' in some countries. This panel will 
present new theoretical and empirical 
work on harm reduction in European 
countries. It is a panel of the joint working 
group between the ISSDP and the Euro-
pean Society of Criminology 
 
Vanessa Gstrein 
 
Ideation, social construction and drug pol-
icy: a scoping review 
Ediomo-Ubong Nelson 
 
Criminalization of drug use and human 
rights: Narratives of police crackdowns in 
Uyo, Nigeria 
 
 
Edgar Guerra 
 
Prohibition or legalization. The dispute 
over medical use or recreational con-
sumption of cannabis in Mexico 
 
 
 
Anna Ross 
 
Developing a critical drug theory: Narra-
tive, knowledge and participation  
Melissa Bone 
 
Human rights, politics and power: for the 
case of the UK’s Cannabis Social Club 
Movement 
 
 
Sharon Sznitman 
 
Do recreational cannabis users, unli-
censed and licensed medical cannabis 
users form a distinct group? 
 
 
 
Eric A. Ratliff 
 
“A totally different atmosphere”: Co-pro-
ducing drug contexts through narrative 
emplacement  
 
 
 
 
 
Jamie Bridge, Christopher Hallam Dave 
Bewley Taylor, Marie Nougier, Martin 
Jelsma 
 
Edging forward: How the UN's language 
on drugs has advanced since 1990  
 
Axel Klein, Gary Potter 
 
The three betrayals of the medical can-
nabis grower: from multiple victimhood to 
reconstruction, redemption and agency  
  
 
3:20 pm – 3:45 pm Conference Closing Ceremony and invitation to ISSDP 2018: Vancouver, Canada 
 
 
 
